Esperion is a commercial-stage pharmaceutical company built around a single drug franchise: bempedoic acid, sold as NEXLETOL (bempedoic acid alone) and NEXLIZET (bempedoic acid combined with ezetimibe) in the U.S., and NILEMDO and NUSTENDI in Europe. These are oral, once-daily pills that lower LDL cholesterol and reduce cardiovascular risk. The drugs work by inhibiting ACLY, an enzyme in the liver's cholesterol synthesis pathway — a different mechanism from statins that avoids the muscle pain that makes statins intolerable for many patients. The core target patient either cannot tolerate statins or needs additional LDL reduction on top of statin therapy. The key clinical asset is the CLEAR Outcomes trial, a ~14,000-patient study that showed bempedoic acid reduced major adverse cardiovascular events by 13% vs. placebo — the first non-statin LDL-lowering therapy to demonstrate this. Esperion sells directly in the U.S. through a sales force of ~155 reps. Internationally, Esperion earns royalties and milestones from partners including Daiichi Sankyo Europe, Otsuka in Japan, and others across Canada, Australia, and Asia. A notable feature of the business model is that Esperion partially monetized its European royalty stream via a royalty purchase agreement with OMERS Life Sciences. Looking ahead, Esperion is pursuing a triple-combination pill combining bempedoic acid, ezetimibe, and a statin, targeting launch around 2027, and has nominated a next-generation ACLY inhibitor for a rare liver disease as its first pipeline candidate beyond cardiovascular.